Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses
Colleen Annesley(Unknown), Rebecca Gardner(Seattle Children's Hospital), Michael C. Jensen(Seattle Children's Hospital), Julie R. Park(Seattle Children's Hospital), Ashley Wilson(Center for Infectious Disease Research), Qian Wu(Cancer Research Center), Julie Rivers(Seattle Children's Hospital), Michael A. Pulsipher(Primary Children's Hospital), Adam J. Lamble(Seattle Children's Hospital), Christopher Brown, Corinne Summers(Seattle Children's Hospital), Stephanie Mgebroff(Bloodworks Northwest), Alan S. Wayne(University of Southern California), Adam Brand, Catherine Lindgren(Unknown)
Cited by 16
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k